Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 27;15(1):64.
doi: 10.1186/s13244-024-01629-4.

The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis

Lanqing Cong #  1 , Yan Deng #  2 , Shuo Cai  3 , Gongzheng Wang  4 , Xinya Zhao  1 , Jingzhen He  2 , Songbo Zhao  5   6 , Li Wang  7
Affiliations

The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis

Lanqing Cong et al. Insights Imaging. .

Erratum in

Abstract

Objectives: To determine the value of periportal hyperintensity sign from gadobenate dimeglumine (Gd-BOPTA)-enhanced hepatobiliary phase (HBP) magnetic resonance imaging (MRI) for predicting clinical outcomes in patients with decompensated cirrhosis.

Methods: A total of 199 cirrhotic patients who underwent Gd-BOPTA-enhanced MRI were divided into control group (n = 56) and decompensated cirrhosis group (n = 143). The presence of periportal hyperintensity sign on HBP MRI was recorded. The Cox regression model was used to investigate the association between periportal hyperintensity sign and clinical outcomes.

Results: There was a significant difference in the frequency of periportal hyperintensity sign on HBP between compensated and decompensated cirrhotic patients (p < 0.05). After a median follow-up of 29.0 months (range, 1.0-90.0 months), nine out of 143 patients (6.2%) with decompensated cirrhosis died. Periportal hyperintensity sign on HBP MRI was a significant risk factor for death (hazard ratio (HR) = 23.677; 95% confidence interval (CI) = 4.759-117.788; p = 0.0001), with an area under the curve (AUC) of 0.844 (95% CI = 0.774-0.899). Thirty patients (20.9%) developed further decompensation. Periportal hyperintensity sign on HBP MRI was also a significant risk factor for further decompensation (HR = 2.594; 95% CI = 1.140-5.903; p = 0.023).

Conclusions: Periportal hyperintensity sign from Gd-BOPTA-enhanced HBP MRI is valuable for predicting clinical outcomes in patients with decompensated cirrhosis.

Critical relevance statement: Periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase magnetic resonance imaging is a new noninvasive method to predict clinical outcomes in patients with decompensated cirrhosis.

Key points: • There was a significant difference in the frequency of periportal hyperintensity sign on HBP between compensated and decompensated cirrhotic patients. • Periportal hyperintensity sign on the hepatobiliary phase was a significant risk factor for death in patients with decompensated cirrhosis. • Periportal hyperintensity sign on the hepatobiliary phase was a significant risk factor for further decompensation in patients with decompensated cirrhosis.

Keywords: Gadobenate dimeglumine, Periportal hyperintensity sign, Liver cirrhosis, Magnetic resonance imaging, Clinical outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The pre-contrast T1-weighted image (a) and HBP image (b) were selected from a 57-year-old compensated cirrhotic patient. Periportal hyperintensity on HBP is not observed in this patient. The pre-contrast T1-weighted image (c) and HBP image (d) were selected from a 48-year-old decompensated cirrhotic patient. Periportal hyperintensity on HBP is observed (black arrow) in this patient. HBP, hepatobiliary phase
Fig. 2
Fig. 2
Kaplan–Meier curves for patients with decompensated cirrhosis. a Cumulative incidence of death in patients with periportal hyperintensity sign on HBP compared to those without the sign. b Cumulative incidence of further decompensation in patients with periportal hyperintensity sign on HBP compared to those without the sign. HBP, hepatobiliary phase
See this image and copyright information in PMC

References

    1. Jang JW, Choi JY, Kim YS, et al. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2018;16(12):1954–1963. doi: 10.1016/j.cgh.2018.04.063. - DOI - PubMed
    1. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 1992;103(5):1630–1635. doi: 10.1016/0016-5085(92)91188-A. - DOI - PubMed
    1. European Association for the Study of the Liver Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi: 10.1016/j.jhep.2018.03.024. - DOI - PubMed
    1. Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61(6):1809–1820. doi: 10.1002/hep.27723. - DOI - PubMed
    1. Langberg KM, Kapo JM, Taddei TH. Palliative care in decompensated cirrhosis: a review. Liver Int. 2018;38(5):768–775. doi: 10.1111/liv.13620. - DOI - PubMed

LinkOut - more resources